Interleukin-10 facilitates the selection of patients for systemic thrombolysis

BMC Neurology

Volumn 13, Issue , 2013, Pages

  Rodríguez Yáñez, Manuel ^a   Castellanos, Mar ^b   Sobrino, Tomás ^a   Brea, David ^c   Ramos Cabrer, Pedro ^a   Pedraza, Salvador ^b   Castiñeiras, José A ^d   Serena, Joaquín ^b   Dávalos, Antonio ^c   Castillo, José ^a   Blanco, Miguel ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b HOSPITAL JOSEP TRUETA   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d University Hospital of Santiago de Compostela   (Spain)

Author keywords

Interleukin 10; Ischemic stroke; MRI; Thrombolysis

Indexed keywords

ALTEPLASE; BIOLOGICAL MARKER; FIBRINOLYTIC AGENT; GELATINASE B; GLUTAMIC ACID; INTERLEUKIN 10; INTERLEUKIN 6; NEURON SPECIFIC ENOLASE; TUMOR NECROSIS FACTOR ALPHA; IL10 PROTEIN, HUMAN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD CHEMISTRY; BRAIN ISCHEMIA; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION WEIGHTED IMAGING; ELECTROCHEMILUMINESCENCE IMMUNOASSAY; ENZYME ACTIVITY; FEMALE; HOSPITAL ADMISSION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROIMAGING; OUTCOME ASSESSMENT; PATIENT SELECTION; PERFUSION WEIGHTED IMAGING; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANKIN SCALE; SENSITIVITY AND SPECIFICITY; SERUM; SINGLE BLIND PROCEDURE; STROKE PATIENT; TREATMENT DURATION; TREATMENT OUTCOME; BLOOD; FIBRINOLYTIC THERAPY; MAGNETIC RESONANCE ANGIOGRAPHY; MIDDLE AGED; PATHOLOGY; PROCEDURES; STANDARDS; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; BRAIN ISCHEMIA; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INTERLEUKIN-10; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84879043783     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-13-62     Document Type: Article

References (26)

1. Heiss WD. The concept of the penumbra: can it be translated to stroke management?. Int J Stroke 2010, 5:290-295. 10.1111/j.1747-4949.2010.00444.x, 20636712.
2. Schellinger PD, Bryan RN, Caplan LR, et al. Evidence-based guideline: the role of diffusion and perfusion MRI for the diagnosis of acute ischemic stroke: report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology 2010, 75:177-185. 10.1212/WNL.0b013e3181e7c9dd, 2905927, 20625171.
3. Mishra NK, Albers GW, Davis SM, et al. Mismatch-based delayed thrombolysis: a meta-analysis. Stroke 2010, 41:e25-e33. 10.1161/STROKEAHA.109.566869, 19926836.
4. Davalos A, Blanco M, Pedraza S, et al. The clinical-DWI mismatch: a new diagnostic approach to the brain tissue at risk of infarction. Neurology 2004, 62:2187-2192. 10.1212/01.WNL.0000130570.41127.EA, 15210880.
5. Prosser J, Butcher K, Allport L, et al. Clinical-diffusion mismatch predicts the putative penumbra with high specificity. Stroke 2005, 36:1700-1704. 10.1161/01.STR.0000173407.40773.17, 16020762.
6. Tei H, Uchiyama S, Usui T. Clinical-diffusion mismatch defined by NIHSS and ASPECTS in non-lacunar anterior circulation infarction. J Neurol 2007, 254:340-346. 10.1007/s00415-006-0368-8, 17345045.
7. Janjua N, El-Gengaihy A, Pile-Spellman J, Qureshi AI. Late endovascular revascularization in acute ischemic stroke based on clinical-diffusion mismatch. AJNR Am J Neuroradiol 2009, 30:1024-1027. 10.3174/ajnr.A1474, 19193751.
8. Rodriguez-Yañez M, Sobrino T, Arias S, et al. Early biomarkers of clinical-diffusion mismatch in acute ischemic stroke. Stroke 2011, 42:2813-2818. 10.1161/STROKEAHA.111.614503, 21836082.
9. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008, 25:457-507. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee.
10. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): An observational study. Lancet 2007, 369:275-282. 10.1016/S0140-6736(07)60149-4, 17258667.
11. Adams HPJ, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993, 24:35-41. 10.1161/01.STR.24.1.35, 7678184.
12. White JA, Hart RJ, Fry JC. An evaluation of the Waters Pico-Tag system for the amino-acid analysis of food materials. J Automat Chem 1986, 8:170-177. 10.1155/S1463924686000330, 2547673, 18925132.
13. Kane I, Sandercock P, Wardlaw J. Magnetic resonance perfusion diffusion mismatch and thrombolysis in acute ischaemic stroke: a systematic review of the evidence to date. J Neurol Neurosurg Psychiatry 2007, 78:485-491. 2117840, 17056631.
14. Rohl L, Geday J, Ostergaard L, et al. Correlation between diffusion- and perfusion-weighted MRI and neurological deficit measured by the Scandinavian Stroke Scale and Barthel Index in hyperacute subcortical stroke (< or = 6 hours). Cerebrovasc Dis 2001, 12:203-213. 10.1159/000047705, 11641585.
15. Ebinger M, Iwanaga T, Prosser JF, et al. Clinical-diffusion mismatch and benefit from thrombolysis 3 to 6 hours after acute stroke. Stroke 2009, 40:2572-2574. 10.1161/STROKEAHA.109.548073, 19407226.
16. Terasawa Y, Kimura K, Iguchi Y, et al. Could clinical diffusion-mismatch determined using DWI ASPECTS predict neurological improvement after thrombolysis before 3 h after acute stroke?. J Neurol Neurosurg Psychiatry 2010, 81:864-868. 10.1136/jnnp.2009.190140, 20562433.
17. Deguchi I, Takeda H, Furuya D, et al. Significance of clinical-diffusion mismatch in hyperacute cerebral infarction. J Stroke Cerebrovasc Dis 2011, 20:62-67. 10.1016/j.jstrokecerebrovasdis.2009.11.002, 21187256.
18. Rodriguez-Yañez M, Castillo J. Role of inflammatory markers in brain ischemia. Curr Opin Neurol 2008, 21:353-357. 10.1097/WCO.0b013e3282ffafbf, 18451722.
19. Wunderlich MT, Lins H, Skalej M, Wallesch CW, Goertler M. Neuron-specific enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke. Clin Neurol Neurosurg 2006, 108:558-563. 10.1016/j.clineuro.2005.12.006, 16457947.
20. Arsene D, Vasilescu F, Toader C, Balan A, Popa C, Ardeleanu C. Clinico-pathological correlations in fatal ischemic stroke. An immunohistochemical study of human brain penumbra. Rom J Morphol Embryol 2011, 52:29-38.
21. Castellanos M, Sobrino T, Pedraza S, et al. High plasma glutamate concentrations are associated with infarct growth in acute ischemic stroke. Neurology 2008, 71:1862-1868. 10.1212/01.wnl.0000326064.42186.7e, 18971451.
22. Kaushal V, Schlichter LC. Mechanisms of microglia-mediated neurotoxicity in a new model of the stroke penumbra. J Neurosci 2008, 28:2221-2230.
23. Tedgui A, Mallat Z. Anti-inflammatory mechanisms in the vascular wall. Circ Res 2001, 88:877-887. 10.1161/hh0901.090440, 11348996.
24. Spera PA, Ellison JA, Feuerstein GZ, Barone FC. IL-10 reduces rat brain injury following focal stroke. Neurosci Lett 1998, 251:189-192. 10.1016/S0304-3940(98)00537-0, 9726375.
25. Dietrich WD, Busto R, Bethea JR. Postischemic hypothermia and IL-10 treatment provide long-lasting neuroprotection of CA1 hippocampus following transient global ischemia in rats. Exp Neurol 1999, 158:444-450. 10.1006/exnr.1999.7115, 10415151.
26. Vila N, Castillo J, Davalos A, Esteve A, Planas AM, Chamorro A. Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke. Stroke 2003, 34:671-675. 10.1161/01.STR.0000057976.53301.69, 12624290.